Toray Industries (6HK) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Paclitaxel, Ramucirumab, Trk-950 | Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase II | Recruiting | A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer | Aug 29, 2023 | ― |
| Nivolumab, Trk-950 | Melanoma, Solid Tumor | phase1AndPhase2 | Active Not Recruiting | A Study of TRK-950 in Patients With Advanced Solid Tumors | Jun 14, 2022 | ― |
| Gemcitabine, Pembrolizumab, Bevacizumab, Nivolumab, Irinotecan, Paclitaxel, Carboplatin, Cisplatin, Leucovorin, Ramucirumab, Pld, Trk-950, 5-Fu, Imiquimod Cream | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Ovarian Cancer, Bladder Cancer, Melanoma, Colorectal Cancer, Renal Cell Carcinoma, Solid Tumor, Gastric Cancer, Cholangiocarcinoma, Primary Peritoneal Cancer, Palpable Subcutaneous Malignant Lesions | Phase I | Active Not Recruiting | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | Mar 07, 2019 | ― |
| Trk-950 | Colon Cancer, Cholangiocarcinoma, Locally Advanced Or Metastatic Solid Carcinomas | Phase I | Completed | A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors | Nov 29, 2016 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Paclitaxel, Ramucirumab, Trk-950 | Phase II | Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Recruiting | A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer | Aug 29, 2023 | ― |
| Nivolumab, Trk-950 | phase1AndPhase2 | Melanoma, Solid Tumor | Active Not Recruiting | A Study of TRK-950 in Patients With Advanced Solid Tumors | Jun 14, 2022 | ― |
| Gemcitabine, Pembrolizumab, Bevacizumab, Nivolumab, Irinotecan, Paclitaxel, Carboplatin, Cisplatin, Leucovorin, Ramucirumab, Pld, Trk-950, 5-Fu, Imiquimod Cream | Phase I | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Ovarian Cancer, Bladder Cancer, Melanoma, Colorectal Cancer, Renal Cell Carcinoma, Solid Tumor, Gastric Cancer, Cholangiocarcinoma, Primary Peritoneal Cancer, Palpable Subcutaneous Malignant Lesions | Active Not Recruiting | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | Mar 07, 2019 | ― |
| Trk-950 | Phase I | Colon Cancer, Cholangiocarcinoma, Locally Advanced Or Metastatic Solid Carcinomas | Completed | A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors | Nov 29, 2016 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Toray Industries (DE:6HK) have in its pipeline
Toray Industries DE:6HK is currently developing the following drugs: Paclitaxel, Ramucirumab, Trk-950, Nivolumab, Trk-950, Gemcitabine, Pembrolizumab, Bevacizumab, Nivolumab, Irinotecan, Paclitaxel, Carboplatin, Cisplatin, Leucovorin, Ramucirumab, Pld, Trk-950, 5-Fu, Imiquimod Cream, Trk-950. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
